ATP5ME抗体;ATP5ME Antibody—艾普蒂 新品

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane 1-5: Human liver tissue, PC-3 cell, 293T cell, Human fetal liver tissue, Human heart tissue lysates, Primary antibody: P13494(ATP5ME Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 15 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P13494(ATP5ME Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P13494(ATP5ME Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The ATP5ME antibody targets the ATP synthase membrane subunit e (ATP5ME), a crucial component of mitochondrial ATP synthase (Complex V). This enzyme, located in the inner mitochondrial membrane, catalyzes ATP production during oxidative phosphorylation. ATP5ME, also known as subunit e, is part of the stator stalk that stabilizes the complex’s structure and facilitates proton translocation. It plays a regulatory role in ATP synthase dimerization and cristae morphology, impacting mitochondrial energy metabolism and cellular homeostasis.

Antibodies against ATP5ME are widely used in research to study mitochondrial function, bioenergetics, and diseases linked to mitochondrial dysfunction, such as neurodegenerative disorders, cancer, and metabolic syndromes. They enable detection of ATP5ME expression levels via Western blotting, immunofluorescence, or immunohistochemistry, aiding in investigations of mitochondrial dynamics, apoptosis, and stress responses. Commercial ATP5ME antibodies are typically raised in rabbits or mice using synthetic peptides or recombinant proteins, with validation in knockout controls or siRNA-treated samples to ensure specificity. Researchers utilize these tools to explore tissue-specific expression patterns, mitochondrial remodeling during disease progression, and therapeutic interventions targeting energy metabolism pathways.